Ligand Pharmaceuticals LGND Share-Based Payment Award Options Outstanding - Number
Share-Based Payment Award Options Outstanding - Number at other companies
Other financials
Where this comes from
Reported directly by Ligand Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber.
The official record: Ligand Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ligand Pharmaceuticals's share-based payment award options outstanding - number.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ligand Pharmaceuticals's share-based payment award options outstanding - number?
- Ligand Pharmaceuticals (LGND) reported share-based payment award options outstanding - number of 2.2M in Q1 2026.
- How has Ligand Pharmaceuticals's share-based payment award options outstanding - number changed year-over-year?
- Ligand Pharmaceuticals's share-based payment award options outstanding - number decreased by 12.1% year-over-year, from 2.5M to 2.2M.
- What is the long-term trend for Ligand Pharmaceuticals's share-based payment award options outstanding - number?
- Over 3 years (2022 to 2025), Ligand Pharmaceuticals's share-based payment award options outstanding - number has grown at a -12.5% compound annual growth rate (CAGR), from 3M to 2M.
- What does share-based payment award options outstanding - number mean?
- This is the total count of stock options granted to employees and directors that remain unexercised at the reporting date. It reflects the total volume of potential equity claims currently held by the workforce. This metric is a key component in calculating fully diluted share counts.